Characteristics of exanthemas in adult-onset COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the study is to evaluate the frequency and study the features of COVID-19 skin manifestations in adults. Materials and methods. 210 case histories of patients aged 18 to 96 years with confirmed coronavirus infection caused by SARS- CoV-2 virus were analyzed. All patients received standard therapy according to temporary guidelines, and other medications as indicated. Results. Skin manifestations were observed in 11 patients. Rashes appeared in patients in the range from 1 to 10 days from the onset of the disease, while urticary and macular-papular rashes were noted at an earlier time - up to 7 days, and hemorrhagic rashes-on the 5th -10th day. The duration of exanthema ranged from 3 to 14 days, with the longest remaining hemorrhagic elements of the rash. The use of enterosorbents in toxicoderma of infectious and medicinal origin is justified and significantly improves the prognosis. Conclusion. Exanthema was observed in COVID-19 in 5.2% of adult patients. The most frequent was urticarial rash (2.9%) and less - macula-papular 2 (1%) and hemorrhagic-type purpura and vesicles with hemorrhagic content - at the 3 (1.4%). Hemorrhagic elements of the rash were detected in patients with a more severe course. The use of enterosorbents suspends the spread of exanthema, prevents the appearance of new rash elements. Zosterin Ultra 60% is recommended as detoxification and enterosorption therapy for COVID-19, including the development of exanthemums, especially for patients with complaints of constipation that provoke other sorbents.

Full Text

Restricted Access

About the authors

Tatiana A. Ruzhentsova

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: ruzhencova@gmail.com
MD, Head, Qinical Research Department; Professor, Educational Center Moscow, Russia

Daria A. Khavkirn

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: havkina@gmail.com
Statistic, Qinical Research Department Moscow, Russia

Pavel V. Chuklyaev

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: pafachka@gmail.com
Methodist, Qinical Research Department Moscow, Russia

Alexandr A. Garbuzov

Central Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: os.vertebra@gmail.com
Methodist, Qinical Research Department Moscow, Russia

Natalia A. Meshkova

I.M. Sechenov First Moscow State Medical University Ministry of Health of Russia (Sechenovskiy University)

Email: nataliaandreevnamesh@gmail.com
3rd-year student, N.F. Filatov Clinical Institute of Children’s Health Moscow, Russia

References

  1. Galvân Casas C., Català A., Carretero Hernândez G., Rodriguez-Jiménez P., Fernândez Nieto D, Rodriguez-Villa Lario А. et. al. Classification of the cutaneous manifestations of COVID -19: a rapid prospective nationwide consensus study in Spain with 375 cases. Brit. J. Dermatol. 2020. https://doi.org/10.1111/bjd.19163
  2. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J. Eur. Acad. Dermatol. Venereol. 2020; 34: e212-3. doi: 10.1111/jdv. 16387.
  3. Tang K., Wang Y., Zhang H., Zheng Q., Fang R., Sun Q. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A briefreview [published online ahead of print, 2020 May 7]. Dermatol. Ther. 2020; e13528. doi: 10.1111/dth.13528
  4. Вялов С.С. Нарушение проницаемости слизистой оболочки как фактор патогенеза функциональных нарушений желудочно-кишечного тракта: обоснование и возможности коррекции. Consilium Medicum 2018; (12): 99-104.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies